Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
Status:
Unknown status
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
30 patients will randomly be selected and will be administered either reboxetine or a
placebo. changes in cognition and behavior will be assessed by computer tests and scales
during a six week study period.